JPMorgan Chase & Co. Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $36.00
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $38.00 to $36.00 in a research note issued to investors on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. DAWN has been the subject of a number of other […]
More Stories
US Business Activity Hits 52-Month High in August: S&P Global
By Andrew Moran Business activity kicked into high gear this month, accelerating at its fastest pace in more than four...
US Imposes Sanctions on Hezbollah Cash Smuggling Ring
By Timothy Frudd The Treasury Department announced sanctions on Aug. 20 against 10 individuals accused of running a cash smuggling...
900 Visas Revoked in Birth Tourism Crackdown: State Department
By Jack Phillips The U.S. Department of State on Aug. 20 said that nearly 900 visas have been revoked since...
A Man on the Inside: Release Date, Trailer, Plot, and Episode Updates
Is your favourite detective, Ted Danson, returning with a season 3 of A Man on the Inside? Fans are looking...
8 Killed After Charter Plane Crashes in Western Alaska: US Military
By AldgraFredly The U.S. military said on Aug. 20 that eight people were killed after a charter plane crashed at...
Israel, Turkey Continue Dispute Over Syria After Airbase Strike
By Evgenia Filimianova Israel and Turkey have deepened their dispute over Syria after Israel defended its strike on a Syrian...